ET Capital

ET Capital is a UK-based investment firm, founded in 1992, specializing in high-growth technology businesses. The firm focuses on science-based companies primarily located within the globally significant clusters around Cambridge, Oxford, and London. They manage a series of funds, including those dedicated to early-stage technology, businesses with potential for scaling in China, and ventures addressing the climate emergency through low carbon and green technologies.

The firm was founded in 1992 by Martin Rigby, who serves as the Managing Director. Prior to establishing ET Capital, Rigby had over 30 years of experience as a venture capital investor, including a tenure at 3i plc focusing on early-stage technology investments. The firm's strategy involves backing ambitious entrepreneurs to build outstanding businesses, with a track record of successful exits, including public flotations and profitable acquisitions.

ET Capital's notable investments include ADC Therapeutics SA, which successfully floated on the NYSE in May 2020 with a valuation of $1.3 billion. Another significant exit was Carbon Engineering Limited, a start-up focused on CO2 capture, which was acquired by Occidental Petroleum for $1.1 billion in August 2023. The firm has also seen portfolio companies like Spirogen acquired by AstraZeneca and MJog sold to Kry Group.

The leadership team comprises experienced investors such as Martin Rigby, David Gill (Non-executive Director), and James Griffiths (Investment Director). David Gill brings a background in investment banking and corporate finance, having previously been Head of Technology & Innovation for HSBC's UK bank. James Griffiths specializes in low carbon and green technology investments, with over 15 years of experience in technology investing and a focus on innovation funding in East and Southeast Asia.